Opsumit (macitentan) costs roughly $10,000 to $15,000 per month without insurance, placing it among the most expensive daily oral medications in the U.S. Several factors drive that price: it treats a rare disease with a small patient population, it required a massive clinical trial to win approval, it can only be dispensed through certified specialty pharmacies, and Johnson & Johnson paid $30 billion for the company that developed it. Here’s how each of those factors stacks up.
A Small Patient Pool Means Higher Per-Patient Costs
Opsumit treats pulmonary arterial hypertension (PAH), a progressive disease where high blood pressure in the lungs gradually damages the heart. PAH affects an estimated 15 to 50 people per million, making it a textbook rare disease. The FDA granted Opsumit orphan drug designation in September 2009, four years before it reached the market.
Orphan drug status exists specifically to make rare disease drugs financially viable. Developing a medication costs hundreds of millions of dollars regardless of how many people will take it. When only a small number of patients exist, the manufacturer spreads those costs across far fewer prescriptions, which pushes the price per patient dramatically higher. The orphan drug designation also gave Opsumit seven years of market exclusivity after its October 2013 approval, shielding it from generic competition until October 2020. During that window, no other company could sell the same molecule for the same condition.
A Large, Long Clinical Trial Behind Approval
The pivotal trial that got Opsumit approved, called SERAPHIN, was unusually ambitious for a rare disease drug. It enrolled 742 patients across multiple countries and ran from March 2008 through November 2012. That’s more than four years of tracking patients, staffing research sites, and collecting data before the drug even reached regulators.
Most rare disease trials enroll a few hundred patients at most, and many rely on shorter-term surrogate endpoints like exercise capacity. SERAPHIN instead measured harder outcomes: disease progression, hospitalization, the need to escalate to more invasive treatments, and death. This kind of long-duration, event-driven trial is significantly more expensive to run than a shorter study, but it produced the type of evidence regulators and insurers look for. Those development costs get baked into the drug’s price for years afterward.
A $30 Billion Acquisition Added Financial Pressure
Opsumit was originally developed by Actelion, a Swiss biotech company that specialized in PAH treatments. In 2017, Johnson & Johnson acquired Actelion for $30 billion in an all-cash deal, paying $280 per share. Opsumit was one of the crown jewels of that acquisition, alongside two other PAH drugs (Uptravi and Tracleer).
When a pharmaceutical company pays that kind of premium to acquire a portfolio, it needs the acquired drugs to generate enough revenue to justify the investment. That financial reality creates strong incentive to maintain or increase pricing on existing products. J&J didn’t buy Actelion expecting to lower Opsumit’s price. The acquisition cost effectively becomes another layer of expense that the drug’s revenue must cover.
Restricted Distribution Adds Overhead
You can’t pick up Opsumit at a regular pharmacy. Because the drug can cause severe birth defects, the FDA requires it to be distributed through a restricted safety program called a REMS (Risk Evaluation and Mitigation Strategy). Under this program, prescribers must be certified and complete training. All female patients must enroll in the REMS before starting the medication, and women of reproductive potential must follow strict pregnancy testing and contraception requirements. Only certified pharmacies can dispense the drug, and it’s typically mailed to patients by a specialty pharmacy.
This specialty pharmacy model adds cost at every step. Certified pharmacies carry additional compliance and reporting burdens. The enrollment and verification process requires dedicated staff and infrastructure. These logistics aren’t cheap, and they contribute to higher prices compared to medications that flow through standard retail pharmacy channels.
Limited Competition Until Recently
Although Opsumit’s orphan drug exclusivity ended in 2020, generic competition has been slow to materialize. The first generic version (from Aurobindo Pharma) received FDA approval in April 2023, and several more have been approved since then. As of late 2025, six manufacturers hold FDA approval for generic macitentan. However, the generic versions do not yet appear to be commercially available, meaning patients still face brand-name pricing in practice.
Even when generics do launch, the REMS program creates an additional hurdle. Generic manufacturers must either join the existing restricted distribution program or establish their own, which slows the typical pattern where generic entry quickly drives prices down. For now, the lack of real-world generic availability keeps Opsumit’s price anchored near its original level.
Clinical Value Relative to Older Options
Opsumit belongs to a class of drugs called endothelin receptor antagonists, which relax blood vessels in the lungs. Older drugs in the same class exist, but Opsumit’s pricing reflects some clinical advantages. In comparative studies, patients on macitentan had a 19% lower risk of PAH-related hospitalization and a 20% lower risk of hospitalization from any cause compared to patients on older drugs in the same class. Those reductions matter in a disease where a single hospitalization can cost tens of thousands of dollars.
That said, the same research found no significant differences in disease progression, overall mortality, or combined morbidity and mortality outcomes between macitentan and older alternatives. So the clinical advantage is real but specific: fewer hospitalizations, not necessarily longer survival. Insurers and pharmacy benefit managers weigh these incremental benefits when deciding whether to cover the drug, and manufacturers use the hospitalization data to justify premium pricing.
Financial Help That Offsets the Sticker Price
If you’re facing Opsumit’s price tag, the actual out-of-pocket cost may be far lower than the list price. Johnson & Johnson runs a savings program for patients with commercial insurance that drops the co-pay to $5 per prescription fill, with no income verification required. This program doesn’t apply to Medicare, Medicaid, or other government-funded coverage.
For uninsured patients or those whose insurance doesn’t fully cover the cost, J&J also offers a patient assistance program that can provide the medication at no cost for up to one year, provided you meet income eligibility requirements. These programs exist in part because the manufacturer knows the list price is unaffordable for most individuals paying out of pocket. They also help ensure that the high list price, which generates revenue from insurers, doesn’t prevent patients from actually filling their prescriptions.